stockrowSolventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024.
- Revenue
- −7.01%
- EPS
- −101.0%
- Free cash flow
- +561.9%
- Total debt
- −90.1%
Quarter to September 2026, against a year earlier
Follow SOLV
Alert me
Solventum Corporation (SOLV) Return on equity
Solventum Corporation's return on equity over the twelve months to 30 September 2026 was 3.19%, down 35.7 percentage points from fiscal 2025 (38.9%). That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 38.9% | 32.31 |
| FY2024 | 6.55% | 6.55 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | — |
Return on equity against peers
| Company | Return on equity |
|---|---|
| WST West Pharmaceutical Services, Inc. compare | 21.2% |
| ATR AptarGroup, Inc. compare | 9.86% |
| COO The Cooper Companies, Inc. compare | 6.84% |
| AVTR Avantor, Inc. compare | 5.91% |
| SOLV Solventum Corporation | 3.19% |
| ALGN Align Technology, Inc. compare | 0.00% |
| RGEN Repligen Corporation compare | −0.57% |
| BLCO Bausch + Lomb Corporation compare | −1.71% |
| BAX Baxter International Inc. compare | −10.6% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on SOLV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement